New combo therapy aims to help bariatric patients drop weight and kick the habit before surgery

NCT ID NCT07224087

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This early-stage study at Yale is testing whether a combination of two medications (naltrexone and bupropion) plus cognitive-behavioral therapy can help people who are considering bariatric surgery lose weight and stop smoking. Twenty participants will receive the treatment for four months. The main goal is to see if the program is feasible and acceptable, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Naltrexone and Bupropion
What this could lead to
If successful, this could point toward an effective pre-surgery program that helps patients lose weight and stop smoking before bariatric surgery, potentially improving surgical outcomes.
What could go wrong
This is a very early Phase 1 pilot with only 20 participants, so results may not apply broadly. The medications have known side effects and interactions, and the program may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARIATRIC SURGERY PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medical University of South Carolina

    Charleston, South Carolina, 29407, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.